Shares of Curanex Pharmaceuticals (NASDAQ: CURX) plummeted 9.75% in Tuesday's intraday trading session, following the announcement of its initial public offering (IPO) pricing. The developmental stage pharmaceutical company, focused on discovering and developing botanical drugs for inflammatory diseases, priced its IPO at $4.00 per share, which appears to have disappointed some investors.

Curanex announced the pricing of 3,750,000 shares of common stock, aiming to raise $15 million in gross proceeds before deducting underwriting discounts and offering expenses. The company's shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX" on the same day. The significant drop in share price suggests that the market may have expected a higher valuation or that investors are cautious about the company's prospects.

The proceeds from the IPO are earmarked for several key initiatives, including the development of Curanex's lead product candidate, Phyto-N, for the treatment of ulcerative colitis. The company also plans to conduct FDA-required good laboratory practice toxicology and pharmacokinetic studies for Phyto-N, prepare and submit an Investigational New Drug (IND) application, and use the remaining funds for working capital and other general corporate purposes. Despite the initial negative market reaction, the success of these initiatives will likely play a crucial role in the company's future stock performance and its ability to bring innovative treatments to market.